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Abstract 27 
Objective: To dosimetrically compare the intensity-modulated-arc-therapy (IMAT), 28 
CyberKnife therapy (CK), single fraction interstitial high-dose-rate (HDR) and low-dose-rate 29 
(LDR) brachytherapy (BT) in low-risk prostate cancer. 30 
Methods: Treatment plans of ten patients treated with CK were selected and additional plans 31 
using IMAT, HDR and LDR BT were created on the same CT images. The prescribed dose was 32 
2.5/70Gy in IMAT, 8/40Gy in CK, 21Gy in HDR and 145Gy in LDR BT to the prostate gland. 33 
EQD2 dose-volume parameters were calculated for each technique and compared. 34 
Results: EQD2 total dose of the prostate was significantly lower with IMAT and CK than with 35 
HDR and LDR BT, D90 was 79.5Gy, 116.4Gy, 169.2Gy and 157.9Gy (p<0.001). However, 36 
teletherapy plans were more conformal than BT, COIN was 0.84, 0.82, 0.76 and 0.76 (p<0.001), 37 
respectively. The D2 to rectum and bladder were lower with HDR BT than with IMAT, CK and 38 
LDR BT, it was 66.7Gy, 68.1Gy, 36.0Gy and 68.0Gy (p=0.0427), and 68.4Gy, 78.9Gy, 51.4Gy 39 
and 70.3Gy (p=0.0091) in IMAT, CK, HDR and LDR BT plans, while D0.1 to urethra was lower 40 
with both IMAT and CK than with BTs: 79.9Gy, 88.0Gy, 132.7Gy and 170.6Gy (p<0.001). D2 41 
to hips was higher with IMAT and CK, than with BTs: 13.4Gy, 20.7Gy, 0.4Gy and 1.5Gy 42 
(p<0.001), while D2 to sigmoid, bowel bag, testicles and penile bulb was higher with CK than 43 
with the other techniques. 44 
Conclusions: HDR monotherapy yields the most advantageous dosimetrical plans, except for 45 
the dose to urethra, where IMAT seems to be the optimal modality in the radiotherapy of low-46 
risk prostate cancer. 47 
Keywords: prostate cancer; intensity-modulated arc therapy; Cyberknife therapy; interstitial 48 
high-dose-rate brachytherapy; interstitial low-dose-rate brachytherapy 49 
 50 
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Introduction 52 
Prostate cancer is the second most common cancer in men worldwide and the fourth most 53 
commonly occurring cancer overall. There were 1.3 million new cases in 2019.  It is estimated 54 
that 33.000 deaths from this disease will occur this year [1]. The standard of care in the curative 55 
treatment of low- and selected intermediate-risk prostate cancer is external beam radiotherapy 56 
with intensity-modulated arc therapy (IMAT) or with CyberKnife (CK) technique or interstitial 57 
high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy (BT) [2]. 58 
Since the α/β value of prostate tumour is low, dose escalation has an essential role in the 59 
development of all radiotherapy modalities [3-5]. The more complex the techniques, the more 60 
they are capable of escalating the dose to the tumour, while sparing the organs at risk (OARs).  61 
The IMAT technique results improved OAR sparing with acceptable planning target volume 62 
(PTV) coverage [6]. Stereotactic radiotherapy with CyberKnife demonstrated favourable 63 
tumour control, better patient-reported quality of life and lower levels of toxicity [7]. The use 64 
of BT, as a boost has been linked with improved biochemical-progression-free and overall 65 
survival [8,9]. What is more, modern LDR monotherapy approach results in improved quality 66 
of life, as a consequence of lower acute urinary and rectal toxicity [11], with the dose coverage 67 
of the target volume (D90, the minimum dose delivered to 90% of the prostate) correlating with 68 
local tumour control [11], and the dose of the most exposed part of the OARs with normal tissue 69 
toxicity [12]. 70 
Despite the wide-spread application of these state-of-the-art techniques, no detailed 71 
analysis of all of these treatment techniques exists. Leszczyński et al. compared the dose 72 
distributions of intensity-modulated prostate radiotherapy versus IMAT technique [13]. Yang 73 
et al. investigated the dosimetric differences among IMAT, HDR and LDT BT for 10 patients, 74 
but HDR BT was not a single fraction monotherapy in their study [14]. Andrzejewski et al. 75 
studied the feasibility of dominant intraprostatic lesion (DIL) boosting using IMAT, proton 76 
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therapy or HDR BT for 12 patients [15]. Georg et al. examined the optimal radiotherapy 77 
technique among IMAT, proton-, carbon-ion therapy and HDR or LDR BT, but HDR BT was 78 
not a single fraction monotherapy for the 10 studied patients [2]. Morton et al. studied HDR 79 
and LDR BT techniques against IMAT external beam therapy [16]. Fuller et al. dosimetrically 80 
compared CK and HDR BT plans for their first 10 patients treated with CK, but not all of the 81 
OARs relevant to CK treatment were evaluated [17]. King examined HDR versus LDR BT as 82 
monotherapy and boost in a radiobiological model [18]. Skowronek made a practical 83 
comparison between HDR and LDR prostate BT [19]. 84 
At our institute, all of the four widely used treatment techniques are available. To take 85 
the advantage of this situation, the aim of the present study is a detailed dosimetric comparison 86 
of intensity-modulated-arc-therapy, CyberKnife therapy, interstitial high-dose-rate and low-87 
dose-rate brachytherapy, as monotherapy in low-risk prostate cancer. 88 
Materials and methods 89 
Ten CK plans of patients with low- and selected intermediate-risk prostate cancer treated at our 90 
institute were included in this study. Selection criteria for treatment were the following: 91 
PSA<15 ng/mL and/or GS≤7 and/or Stage T≤2c [20]. 92 
CK treatments were performed with non-coplanar fields using CyberKnife M6 linear 93 
accelerator (Accuray, Sunnyvale, CA, USA). Gold fiducial markers were implanted into the 94 
prostate gland to guide the placement of radiation beams during treatment. The CTV was 95 
extended by an isotropic 3 mm margin, 8 Gy was delivered to this prostate PTV in each fraction. 96 
A total of 5 fractions (total dose 40 Gy) were given every second working day. For treatment 97 
planning Accuray Precision 1.1 treatment planning system (TPS) (Accuray, Sunnyvale, CA, 98 
USA) was used. The dose was prescribed to the 80−85% isodoses (Fig 1.b). The relative volume 99 
of the PTV receiving at least the prescribed dose (V100) had to be at least 95%. The detailed 100 
description of our treatment method can be found in our previous publication [21]. 101 
6 
 
On the CT series made for CK treatment planning, additional plans using IMAT, HDR and 102 
LDR BT were created using the same contour set. Where urethra was not identifiable on CT 103 
images, it was contoured between the bladder and the penile channel using a 15 mm pearl. 104 
IMAT plans were made in Eclipse v13.7 TPS  (Varian Medical Systems, Palo Alto, USA) with 105 
a beam energy of 10 MV using 2 full arcs (Fig 1.a). CTV was extended using an isotropic 5 106 
mm margin. The prescribed dose was 70 Gy, the dose of the daily fractions was 2.5 Gy for the 107 
PTV. The protocol of our PROMOBRA study was applied for treatment planning in both HDR 108 
and LDR BT plans [22]. The prescribed dose in HDR BT was 21 Gy (V100≥95%) to the CTV 109 
of the CK plan, as the BT PTV, in a single treatment fraction using Ir-192 radioactive source. 110 
HIPO method was used to optimize the plans in the Oncentra Prostate v3.1 TPS (Elekta 111 
Brachytherapy, Veendendaal, The Netherlands) (Fig 1.c). In LDR BT the prescribed dose was 112 
145 Gy (V100≥95%) to the same CTV. IPSA optimisation method in the Oncentra Prostate 113 
v3.1 TPS (Elekta Brachytherapy, Veendendaal, The Netherlands) was used to calculate the 114 
virtual positions of the I-125 isotopes (Fig 1.d). The detailed description of our treatment 115 
method can be found in our previous publications [23-26]. 116 
The equivalent dose given in 2 Gy fractions (EQD2) was calculated for each technique 117 
using the linear-quadratic radiobiological model [27,28]. The α/β of prostate was assumed 1.5 118 
Gy, while for OARs 3 Gy was used [29,30]. 1 year was estimated in LDR BT as overall 119 
treatment time, as during this time 89% of the prescribed dose is delivered. The following dose-120 
volume parameters were used for quantitative evaluation of plans: 121 
D90: the minimum dose delivered to 90% of PTV (Gy); 122 
COIN: conformal index [31]; 123 
D0.1(x), D2(x): the minimal dose of the most exposed 0.1 and 2 cm3 of the critical organ 124 
x (Gy), 125 
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where x: rectum (r), urethra (u), bladder (b), hips (h), sigmoid (s), bowel bag (bb), testicles (t) 126 
and penile bulb (p). 127 
Friedman ANOVA and Fisher-LSD (Least Significant Difference) post-hoc tests were used 128 
(Statistica 12.5, StatSoft, Tulsa, OK, USA) to compare EQD2 dose-volume parameters of 129 
IMAT, CK, HDR and LDR BT techniques. 130 
Results 131 
The mean volume of the PTV was 105.7 cm3 (42.2-189.3 cm3) in IMAT, 85.5 cm3 (31.5-159.2 132 
cm3) in the CK and 61.8 cm3 (19.8-126.2 cm3) in both BT plans (which is equal to the original 133 
CTV) on average. We found that EQD2 total dose of the prostate was significantly lower with 134 
IMAT and CK than with HDR and LDR BT, D90 was 79.5 Gy, 116.4 Gy, 169.2 Gy and 157.9 135 
Gy (p<0.001). However, IMAT and CK plans were more conformal than BT plans, COIN were 136 
0.84, 0.82, 0.76 and 0.76 (p<0.001). 137 
In our comparison, the D2 to rectum and bladder were lower with HDR BT than with 138 
IMAT, CK and LDR BT, it was 66.7 Gy, 68.1 Gy, 36.0 Gy and 68.0 Gy (p=0.0427), and 68.4 139 
Gy, 78.9 Gy, 51.4 Gy and 70.3 Gy (p=0.0091) in IMAT, CK, HDR and LDR BT plans, while 140 
D0.1 to urethra was lower with both IMAT and CK than with both BT modalities: 79.9 Gy, 88.0 141 
Gy, 132.7 Gy and 170.6 Gy (p<0.001), respectively. D2 to hips was higher with IMAT and CK, 142 
than with BTs: 13.4 Gy, 20.7 Gy, 0.4 Gy and 1.5 Gy (p<0.001), while D2 was higher to other 143 
organs with CK, than with the other techniques: 1.1 Gy, 17.9 Gy, 0.8 Gy and 2.8 Gy (p<0.001) 144 
for sigmoid; 0.9 Gy, 11.2 Gy, 0.7 Gy and 0.8 Gy (p<0.001) for bowel bag; 0.4 Gy, 20.7 Gy, 0.6 145 
Gy and 4.2 Gy (p=0.0017) for testicles; and 4.9 Gy, 10.3 Gy, 1.7 Gy and 3.2 Gy (p=0.0057) for 146 
penile bulb in IMAT, CK, HDR and LDR BT plans. The detailed results can be found in Table 147 
1. 148 
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Discussion 149 
Dose escalation has a fundamental role in the radiotherapy of low- and selected 150 
intermediate-risk prostate cancer [3-5]. Several high-tech teletherapy and BT techniques are 151 
widely used, such as image-guided and intensity-modulated teletherapy, arc therapy, 152 
stereotactic radiotherapy with linear accelerators or CyberKnife and interstitial HDR or LDR 153 
BT [2,3,6-9,11,12]. In the present study, all of the four widely used radiotherapy techniques 154 
(IMAT, CK, HDR and LDR BT) were compared dosimetrically using the linear-quadratic 155 
radiobiological model. 156 
Although these techniques rapidly developed parallelly, the dosimetrical differences 157 
were conspicuous from the beginning. Leszczyński et al. have pointed out that the treatment 158 
delivery time is significantly reduced using IMAT technique compared to intensity-modulated 159 
radiotherapy [13]. Yang et al. [14] concluded that HDR and LDR BT significantly reduce the 160 
dose to rectum, bladder and femoral heads compared with IMAT. The mean EQD2 dose to 161 
urethra was 80.3 Gy in IMAT, 70.2 Gy in HDR and 104.9 Gy in their LDR BT plans. They 162 
stated that for localised prostate cancer, HDR BT provides the advantage in sparing of urethra 163 
compared with IMAT and LDR, however HDR BT was not a single-fraction treatment in this 164 
study. Our results are not in agreement with this, the EQD2 dose to the urethra was the lowest 165 
in IMAT plans, D0.1 was 79.9 Gy. It was higher, 88.0 Gy with CK technique, while more higher 166 
using HDR or LDR BT: 132.7 Gy and 170.6 Gy (all of the differences are significant). In the 167 
terms of the other OARs sparing, HDR resulted the lowest dose. The explanation of this 168 
difference between the studies can be the different fractionation and prescribed dose. Yang et 169 
al. used 78 Gy physical dose in 39 fractions in IMAT, 34 Gy in 4 fractions in HDR and 145 Gy 170 
in 1 fraction in LDR BT plans and calculated only mean dose of the OARs instead of volumetric 171 
doses. 172 
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Andrzejewski et al. studied the feasibility of DIL boosting and concluded that higher 173 
boost doses were achieved using proton therapy compared to IMAT, keeping doses of major 174 
OARs at similar levels, but HDR BT was superior to IMAT and proton therapy, both in terms 175 
of OAR sparing and boosting of the DIL [15]. EQD2 D50 to DIL were 110.7 Gy, 114.2 Gy and 176 
150.1 Gy in IMAT, proton therapy and HDR BT plans, while the mean dose of the rectal wall 177 
was 30.5 Gy, 16.7 Gy and 9.5 Gy, and the mean dose to the bladder wall were 21.0 Gy, 15.6 178 
Gy and 6.3 Gy, respectively. Georg et al. examined the optimal radiotherapy technique in the 179 
radiotherapy of localised prostate cancer and stated that HDR and LDR BT techniques were 180 
clearly superior in terms of bladder and rectal wall sparing, in contrast with IMAT, proton- and 181 
carbon-ion therapy, with lowest values for HDR BT [2]. However, they did not examine the 182 
dose to the urethra. Based on our comparison, also single fraction HDR monotherapy yields the 183 
most advantageous plans, except in terms of the dose to urethra where IMAT proves to be the 184 
optimal modality. 185 
Morton et al. investigated HDR BT against LDR BT and IMAT external beam therapy 186 
in clinical point of view [16]. They concluded that HDR BT enables more consistent implant 187 
quality than LDR BT, with evidence of lower acute and late toxicity. Higher disease control 188 
rates are also reported with HDR monotherapy than with IMAT technique. These clinical results 189 
are in good agreement with our dosimetrical results. HDR BT resulted the most optimal 190 
treatment plans in terms of both dose coverage of the prostate and the dose to OARs, except for 191 
urethra. 192 
Fuller et al. pointed out that urethra dose is lower for virtual CK than for virtual HDR 193 
BT plans, suggesting that CK technique may more effectively limit urethra dose [17]. Bladder 194 
maximum point doses were higher with HDR BT, but bladder dose fall-off beyond the 195 
maximum dose region was more rapid with this technique than using CK therapy. Our study 196 
10 
 
added a new result to this conclusion, specifically using IMAT the dose to the urethra is lower 197 
than CK and both BT modalities. 198 
Based on the radiobiological examination of King, HDR and LDR BT achieve superior 199 
tumour control when compared with IMAT using conventional doses, and HDR BT might 200 
achieve superior tumour control compared with LDR [18]. This result supports the clinical 201 
evidence for equivalent outcomes in localised prostate cancer with either HDR or LDR BT. 202 
However, HDR BT dose escalation regimens might be able to achieve higher biological 203 
effectiveness and hence improved outcomes in contrast to IMAT. In the same manner, in our 204 
plans, higher EQD2 total doses can be reached to the prostate with BT techniques than with 205 
external radiation techniques, and this dose is the lowest using IMAT. 206 
Skowronek [19] demonstrated that all available clinical data regarding HDR and LDR 207 
BT suggests that they are equally effective, stage for stage, in providing high tumour control 208 
rates. The important difference in dosimetric control allows HDR doses to be escalated safely 209 
providing such a flexibility that does not exist for LDR BT. Our examination also gave one vote 210 
for HDR BT, as the most appropriate technique of dose escalation in prostate radiotherapy. 211 
 It has to be mentioned, that in our study, the virtual BT plans were made on the planning 212 
CT of the CK, and this anatomy is not optimal for BT planning. Furthermore, the EQD2 213 
prescribed dose was higher in both BT techniques than in IMAT and CK plans, as the 214 
recommended, clinically used fractionation was applied in our plans. Despite of that, HDR BT 215 
proved to be the optimal choice in the aspects of sparing most of the OARs beside dose coverage 216 
of the prostate. LDR BT resulted in higher dose to the OARs with approximately equivalent 217 
prescribed dose to the prostate. 218 
Conclusions 219 
Using single fraction HDR and LDR BT, total dose of the prostate is higher than with IMAT or 220 
CK techniques, and accordingly dose to urethra is also higher with both BT modalities using 221 
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the recommended fractionation scheme. Dose to rectum and bladder is lower with HDR BT 222 
than with IMAT, CK and LDR BT, while dose to sigmoid, bowel bag, testicles and penile bulb 223 
are higher with CK than using the other examined techniques. Overall, HDR monotherapy 224 
yields the most advantageous plans in the radiotherapy of low- and intermediate risk prostate 225 
cancer, except in terms of the dose to urethra where IMAT proves to be the optimal modality. 226 
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Tables: 330 
EQD2 IMAT CK HDR LDR p* **post hoc 
D90 (Gy) 79.5 116.4 169.2 157.9 <0.001 IMAT,CK 
COIN 0.84 0.82 0.76 0.76 <0.001 
IMAT-
LDR,HDR 
D0.1(r) (Gy) 86.4 80.0 55.3 93.5 0.0280 HDR,LDR 
D2(r) (Gy) 66.7 68.1 36.0 68.0 0.0427 HDR 
D0.1(u) (Gy) 79.9 88.0 132.7 170.6 <0.001 all 
D2(b) (Gy) 68.4 78.9 51.4 70.3 0.0091 HDR 
D0.1(h) (Gy) 17.3 26.5 0.6 2.1 <0.001 IMAT, CK 
D2(h) (Gy) 13.4 20.7 0.4 1.5 <0.001 IMAT, CK 
D0.1(s) (Gy) 1.3 20.7 0.9 3.8 <0.001 CK 
D2(s) (Gy) 1.1 17.9 0.8 2.8 <0.001 CK 
D0.1(bb) (Gy) 1.1 12.1 1.1 1.3 <0.001 CK 
D2(bb) (Gy) 0.9 11.2 0.7 0.8 <0.001 CK 
D0.1(t) (Gy) 0.4 23.0 0.7 4.7 0.0006 CK,LDR 
D2(t) (Gy) 0.4 20.7 0.6 4.2 0.0017 CK,LDR 
D0.1(p) (Gy) 15.2 23.7 3.2 5.0 0.0014 IMAT,CK 
D2(p) (Gy) 4.9 10.3 1.7 3.2 0.0057 IMAT,CK 
Table 1. Mean EQD2 total doses of intensity-modulated arc therapy (IMAT), CyberKnife 331 
(CK), high-dose-rate (HDR) and low-dose-rate (LDR) brachytherapy of prostate cancer. 332 
D90: the minimum dose delivered to 90% of prostate, COIN: conformal index, D0.1(x), 333 
D2(x): the minimal dose of the most exposed 0.1 and 2 cm3 of ‘x’ organ at risk, where x 334 
are rectum (r), urethra (u), bladder (b), hips (h), sigmoid (s), bowel bag (bb), testicles (t) 335 
and penile bulb (p). *Friedman ANOVA **Fisher-LSD post-hoc test. 336 
337 
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Figures: 338 
 339 
Figure 1. Axial CT slide (left) and 3D reconstruction (right) of a prostate intensity-340 
modulated arc therapy (a,), a CyberKnife (b,), an interstitial high-dose-rate prostate 341 
brachytherapy (c,) and an interstitial low-dose-rate prostate brachytherapy plan (d,). 342 
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Red: prostate, yellow: prostatic urethra, light green: bladder, brown: rectum, dark 343 
brown: sigmoid, khaki: bowel bag, slate blue: femoral heads, lavender: penis, purple: 344 
penile bulb, orange: testicles. 345 
